Clinical Trials Directory

Trials / Completed

CompletedNCT00414362

Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin

Status
Completed
Phase
Study type
Observational
Enrollment
1,000 (actual)
Sponsor
University of Pittsburgh · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The information collected will optimize the management of patients with urinary tract infections with secondary bacteremia, primarily with gram negative bacteria especially Escherichia coli. The current IDSA guideline endorses the use of fluoroquinolones and trimethoprim-sulfamethoxazole as the first line agents. However, over use of this empiric regimen could result in in appropriate treatment of bacteremia.

Detailed description

The following information will be collected: age, sex, occupation, hospital location at the time of positive culture (ER, medical ward, ICU etc), prior hospitalization, receipt of outpatient dialysis, home care or other regular medical care (eg, outpatient chemotherapy), presence of invasive devices, receipt of antibiotics, including their type and whether they were adequate for the resistance profile of the organism, prior positive microbiologic cultures, time and location of positive cultures, underlying diseases and severity of illness, presence of urinary or intravascular devices, recent immunomodulative therapies or radiation therapy, physical exam findings, laboratory and radiographical data, antimicrobial usage within 30 days of onset of the infection, microbiological data and resistance patterns, choice of antibiotics once organism identified, bacteriological outcomes, laboratory results, demographic information, medications, clinical outcome,gender, height, weight, ethnicity, and past medical history. We will collect information retrospectively.

Conditions

Timeline

Start date
2007-02-01
Primary completion
2017-06-01
Completion
2017-06-01
First posted
2006-12-21
Last updated
2018-06-12

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00414362. Inclusion in this directory is not an endorsement.